Intermittent Theta-Burst Stimulation (iTBS) as an add-on to Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Post-traumatic Stress Disorder (PTSD)
Intermittent Theta-Burst Stimulation (iTBS) as an add-on to Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Post-traumatic Stress Disorder (PTSD): An Open-label Pilot Study
This open-label pilot study will evaluate the feasibility, safety, tolerability, and preliminary clinical outcomes of adding intermittent theta-burst stimulation (iTBS) to Eye Movement Desensitization and Reprocessing (EMDR) therapy in adults with post-traumatic stress disorder (PTSD), who show insufficient improvement after an initial course of EMDR.
Participants will receive weekly EMDR therapy. After seven EMDR sessions, treatment response will be assessed using the Clinical Global Impression-Improvement scale (CGI-I). Participants with insufficient response will receive add-on iTBS targeted to the right dorsolateral prefrontal cortex (DLPFC) for four weeks while continuing EMDR. Feasibility outcomes include adherence, treatment completion, and dropout rates. Clinical outcomes will include clinician-rated and self-reported measures of PTSD symptoms, depressive symptoms, well-being, and adverse events.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Post-traumatic stress disorder (PTSD) is a disabling psychiatric condition characterized by intrusive traumatic memories, avoidance behaviors, negative alterations in cognition and mood, and persistent hyperarousal. Although trauma-focused psychotherapies such as Eye Movement Desensitization and Reprocessing (EMDR) are recommended as first-line treatments, a substantial proportion of patients continue to meet diagnostic criteria for PTSD despite receiving evidence-based psychotherapy.
Intermittent theta-burst stimulation (iTBS), a brief form of repetitive transcranial magnetic stimulation (rTMS), has demonstrated preliminary efficacy in reducing PTSD symptoms and offers practical advantages due to its short treatment duration.
The present study aims to investigate whether iTBS can be feasibly integrated as an adjunctive intervention for patients who do not respond sufficiently to EMDR therapy alone. This is an investigator-initiated, open-label feasibility study conducted within psychiatric services in the Central Denmark Region.
Eligible adults aged 18 to 70 years with a diagnosis of PTSD, who are referred for EMDR treatment, will be enrolled. Participants will receive standardized EMDR therapy consisting of sixteen weekly 90-minute sessions. Following completion of seven EMDR sessions, treatment response will be evaluated using the Clinical Global Impression-Improvement (CGI-I) scale. Participants rated as having insufficient improvement (CGI-I score ≥3) will be offered add-on iTBS.
The iTBS intervention will be delivered to the right DLPFC using a MagPro R30 stimulator and Cool-B70 coil. Treatment will consist of one daily iTBS session administered five days per week over four weeks for a total of 20 sessions. Participants will continue weekly EMDR therapy throughout the iTBS phase and subsequent follow-up period.
The primary objectives are to evaluate the safety, tolerability, and feasibility of the combined EMDR+iTBS intervention. Feasibility outcomes include treatment adherence, treatment completion rates, and dropout rates. Secondary outcomes include adverse events and changes in PTSD symptom severity measured using clinician-rated and self-reported instruments.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Pernille Kølbæk, MD PhD
- Número de telefone: 004561397432
- E-mail: perpet@rm.dk
Estude backup de contato
- Nome: Ana Lisa Carmo, Psychiatrist
- Número de telefone: 0045 61155056
- E-mail: ANAMAR@rm.dk
Locais de estudo
-
-
-
Aarhus N, Dinamarca
- Aarhus University Hospital
-
Contato:
- Pernille Kølbæk, MD PhD
- Número de telefone: 004561397432
- E-mail: perpet@rm.dk
-
Contato:
- Ana Lisa Carmo, Psychiatrist
- Número de telefone: 0045 61155056
- E-mail: ANAMAR@rm.dk
-
Investigador principal:
- Ana Lisa Carmo, Psychiatrist
-
Horsens, Dinamarca
- Regional Psychiatry Horsens
-
Contato:
- Pernille Kølbæk, MD PhD
- Número de telefone: 004561397432
- E-mail: perpet@rm.dk
-
Contato:
- Thea Grønfeldt, Psychiatrist
- Número de telefone: 00457847 9258
- E-mail: theafaer@rm.dk
-
Investigador principal:
- Pernille Kølbæk, MD PhD
-
Viborg, Dinamarca
- Regional Psychiatry Central Jutland
-
Contato:
- Pernille Kølbæk, MD PhD
- Número de telefone: 004561397432
- E-mail: perpet@rm.dk
-
Investigador principal:
- Ana Lisa Carmo, Psychiatrist
-
Contato:
- Ana Lisa Carmo, Psychiatrist
- Número de telefone: 004561155056
- E-mail: ANAMAR@rm.dk
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Age 18-70 years
- ICD-10 criteria for PTSD (F43.1)
- A minimum total score of 4 (moderately ill) on the Clinical Global Impression-Severity (CGI-S)
- Likely to be able to complete trial participation (16 weeks) without modifications to psychopharmacological treatment, as per the referring doctor's or psychologist's assessment
- Participants must be able and willing to abstain from alcohol consumption during the iTBS treatment period, as required by the TMS Safety Checklist.
Exclusion Criteria:
- Organic mental disorders (F0)
- Currently fulfills the criteria of Active psychoactive substance use or dependence (F1)
- Schizophrenia, schizotypal and delusional disorders (F2), manic episode (F30), or bipolar affective disorder (F31); iv) Mental retardation (estimated IQ <70, as per the referring doctor's or psychologist's assessment)
- Active suicidality
- Any ongoing involuntary/coercive measures
- Any contraindications listed on the TMS Safety Checklist
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: EMDR with add-on iTBS
Participants receive weekly Eye Movement Desensitization and Reprocessing (EMDR) therapy for up to 16 weeks.
After seven EMDR sessions, treatment response is assessed using the Clinical Global Impression-Improvement scale (CGI-I).
Participants with insufficient response receive adjunctive intermittent theta-burst stimulation (iTBS) to the right dorsolateral prefrontal cortex for 20 sessions over 4 weeks while continuing EMDR.
Participants with sufficient response continue EMDR treatment alone.
|
All enrolled participants begin standardized EMDR treatment.
Participants who show insufficient clinical improvement after seven EMDR sessions receive adjunctive intermittent theta-burst stimulation (iTBS) while continuing EMDR.
Participants who show sufficient improvement continue EMDR alone.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Drop-out
Prazo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
The primary outcome will be drop-out rates
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Treatment completion rates
Prazo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
The second primary outcome will be treatment completion rates (number of iTBS treatments received out of the planned 20 treatments)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Symptom trajectories
Prazo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Symptom trajectories
Prazo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by the PTSD Checklist for DSM-5 (PCL-5)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Symptom trajectories
Prazo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by International Trauma Questionnaire (ITQ)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Symptom trajectories
Prazo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by the 6-item self-reported Hamilton Depression Rating Scale (HAM-D6-SR)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Adverse event rates
Prazo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Adverse event rates, measured by means of the Transcranial Magnetic Stimulation Sensory Questionnaire (TMSens_Q)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Adverse event rates
Prazo: Time Frame: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Adverse event rates, measured by means of the Aarhus Side Effects Assessment Scale (ASAQ)
|
Time Frame: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Changes in mental well-being
Prazo: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Mental well-being as measured by the World Health Organization 5-item well-being scale (WHO-5)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Cadeira de estudo: Pernille Kølbæk, Aarhus University Hospital
- Investigador principal: Ana Lisa Carmo, Aarhus University Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 2502681
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .